EndoChoice to Report Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 And Announces Annual Shareholders Meeting Date

Feb 23, 2016, 08:00 ET from EndoChoice Holdings, Inc.

ALPHARETTA, Ga., Feb. 23, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE:  GI) announced today that it will release its fourth quarter and full year 2015 financial results on Thursday, March 3, 2016 before the market open.

EndoChoice will hold a conference call on Thursday, March 3, 2016 at 9:00 a.m. ET to discuss the results. The dial-in numbers are (877) 328-5344 for domestic callers and (412) 317-5469 for international callers. A live webcast of the conference call will be available on the investor relations section of the Company's website at http://investor.endochoice.com.

A replay of the call will be available starting on March 3, 2016 through March 10, 2016. To access the replay, dial (877) 344-7529 for domestic callers and (412) 317-0088 for international callers, with the replay access code 10081531. A webcast replay will also be available in the investor relations section of the Company's website for 90 days following the completion of the call and a transcript will be posted to the investor relations website.

In addition, EndoChoice will hold its annual shareholder meeting on April 29, 2016 at 8 a.m. ET at the company's offices located at 11405 Old Roswell Road, Alpharetta, Georgia 30009.

About EndoChoice: 
Based near Atlanta, Georgia, EndoChoice (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®).  EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.

Company Contact: David Gill, Chief Financial Officer david.gill@endochoice.com    678-585-1040

Investor Contacts:  Nick Laudico or Zack Kubow  The Ruth Group  646-536-7030 / 7020  nlaudico@theruthgroup.com  zkubow@theruthgroup.com 

SOURCE EndoChoice Holdings, Inc.